Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andro Does Not Boost Muscle Mass Or Serum Testosterone Levels - Study

This article was originally published in The Tan Sheet

Executive Summary

Androstenedione supplementation "does not increase serum testosterone concentrations or enhance skeletal muscle adaptations to resistance training in normo-testosterogenic young men and may result in adverse health consequences," Douglas King, PhD, Iowa State University, et al., report in the June 2 Journal of the American Medical Association.
Advertisement

Related Content

FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation
FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation
FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation
Andro study
Andro study
Andro study
Met-Rx, AST To Place Warnings On "Andro" Products Under FTC Settlement
Met-Rx, AST To Place Warnings On "Andro" Products Under FTC Settlement
Met-Rx, AST To Place Warnings On "Andro" Products Under FTC Settlement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel